WELCEFO-CV contains Cefpodoxime 200 mg + Clavulanic Acid 125 mg, combining cephalosporin antibacterial activity with beta-lactamase inhibition for selected susceptible infections. A differentiated PCD Pharma Antibiotic formulation.
To inhibit susceptible beta-lactamases and broaden activity.
No.
Use only on prescription. Confirm allergy history and complete the course. Seek medical advice for severe diarrhea or allergic reactions.
Diarrhea, nausea, vomiting, abdominal discomfort, headache and rash may occur.
WELCEFO-CV: Cefpodoxime inhibits bacterial cell-wall formation, while Clavulanic Acid inhibits certain beta-lactamases, helping protect the beta-lactam antibiotic from enzymatic degradation.
